TOTAL VOLUME:
$134.2b
24H VOL:
$134,145,987
24H TRANSACTIONS:
2,388,728,490
OPEN INTEREST:
$1,441,166,947
406,422
Markets across
30,383
events
MATCHED EVENTS:
2,688
PLATFORM COVERAGE:
5
Polymarket:
39%
VS.
Kalshi:
61%
FDA approves GSK & Spero Therapeutics' Tebipenem HBr?
- Polymarket
FDA approves GSK & Spero Therapeutics' Tebipenem HBr? - Polymarket
1W
News
Positive
Negative
Neutral
Hover marker for details
Vol.
·
Resolved Jun 17, 2026
Closed: Jun 17, 8:00 PM EST
Polymarket
FDA approves GSK & Spero Therapeutics' Tebipenem HBr?
Description
As of market creation, the FDA's expected decision date for the specified application is June 18, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for GSK & Spero Therapeutics's Tebipenem HBr as a treatment for complicated urinary tract infections (cUTIs), including pyelonephritis by July 2, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Polymarket
As of market creation, the FDA's expected decision date for the specified application is June 18, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for GSK & Spero Therapeutics's Tebipenem HBr as a treatment for complicated urinary tract infections (cUTIs), including pyelonephritis by July 2, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Frequently asked questions
Prediction market odds on Polymarket reflect real-time aggregation of trader beliefs and often diverge from traditional analyst forecasts. While sell-side pharmaceutical analysts may issue approval probability estimates based on clinical trial data and regulatory precedent, prediction markets incorporate broader information including market sentiment, competitive dynamics, and real-time developments. Comparing Polymarket odds to published analyst consensus can reveal whether traders are pricing in more optimism or skepticism than the research community. These differences highlight how decentralized markets may weight regulatory risk, manufacturing readiness, and commercial factors differently than institutional forecasters.
On Polymarket, this event is priced as a binary outcome contract reflecting the probability of FDA approval for Tebipenem HBr by the resolution deadline. On Polymarket, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. Traders buy and sell shares representing YES (approval) or NO (rejection), with the contract price directly indicating implied approval odds. Polymarket's automated market maker mechanism ensures continuous liquidity and price discovery. As new clinical results, regulatory feedback, or company milestones emerge, traders adjust positions, moving the price to reflect updated consensus. The market remains active until Jun 18, 2026, when the outcome is determined and settled based on official FDA action.
The market resolves on Jun 18, 2026. Resolution is determined by whether the FDA issues an approval decision for Tebipenem HBr from GSK and Spero Therapeutics on or before that date. The outcome hinges on official FDA regulatory action, including any standard or accelerated approval pathway. Traders should monitor FDA communications, clinical trial announcements, and regulatory timelines leading up to the deadline. Any formal approval announcement from the FDA or the companies will be the definitive resolution trigger. Markets typically resolve within hours of official confirmation.
Key catalysts include Phase 3 clinical trial results demonstrating efficacy and safety, FDA feedback letters or meeting minutes, competitive approvals in the same antibiotic class, manufacturing or supply chain updates, and company earnings calls or investor presentations. Regulatory actions such as Breakthrough Therapy or Fast Track designations could accelerate timelines and boost approval odds. Conversely, safety signals, efficacy shortfalls, or manufacturing delays could reduce market conviction. Media coverage of resistant bacterial infections and antibiotic demand also influences sentiment. Traders monitor FDA meeting calendars, clinical trial databases, and company filings for real-time signals that reshape approval probability.
